StreetAlpha.app
Home › Stocks › HRMY

Harmony Biosciences Holdings, Inc. (HRMY)

Healthcare
$32.59
▼ −1.18%
LAST CLOSE · NOV 20

Harmony Biosciences develops and sells WAKIX for narcolepsy and other treatments for rare neurological diseases. It last closed at $32.59 on Nov 20, down 1.18% on the day. The next earnings report for HRMY is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, HRMY reported EPS of $0.81 on revenue of $268.9M, with revenue up 12.3% from a year ago. Over its last 8 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months HRMY insiders bought $0 of stock on the open market and sold $6.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is HRMY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold HRMY.

Key Stats

Last 12 months
Results
Revenue
$989.4M
+19.8% vs a year ago
Net income
$178.6M
−3.8% vs a year ago
EPS (diluted)
$3.02
−4.7% vs a year ago
Gross margin
74.0%
$732.4M gross profit
Valuation
Market cap
$1.9B
58.7M shares
P/E
10.8
Price over 12 month EPS
Price to sales
1.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$647.1M
At Sep 30
Debt
$149.1M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
58.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $305.4M$305.4MFY2021FY2022: $437.9M$437.9MFY2022FY2023: $582.0M$582.0MFY2023FY2024: $714.7M$714.7MFY2024FY2025: $868.5M$868.5MFY2025

From HRMY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.81
Quarter ended Sep 2026
Year ago EPS
$0.87
−6.9% on a GAAP basis
Revenue
$268.9M
+12.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.85Dec '24Mar 2025: $0.78Mar '25Jun 2025: $0.68Jun '25Sep 2025: $0.87Sep '25Dec 2025: $0.39Dec '25Mar 2026: $0.55Mar '26Jun 2026: $1.28Jun '26Sep 2026: $0.81Sep '26Latest $0.81
Revenue by quarter
Dec 2024: $201.3MDec '24Mar 2025: $184.7MMar '25Jun 2025: $200.5MJun '25Sep 2025: $239.5MSep '25Dec 2025: $243.8MDec '25Mar 2026: $215.4MMar '26Jun 2026: $261.3MJun '26Sep 2026: $268.9MSep '26Latest $268.9M
How HRMY moved after its last 8 reports
Average move the session after a report ±5.3%
Nov 4, 2026Time not announced−7.0%
Jul 16, 2026Time not announced−3.9%
May 7, 2026Time not announced−4.2%
Feb 24, 2026Time not announced+4.9%
Jan 12, 2026Time not announced−0.7%
Oct 23, 2025Time not announced+12.7%
Aug 5, 2025Time not announced−1.7%
May 6, 2025Time not announced+7.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on HRMYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on HRMY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on HRMY

Technical Analysis

HRMY · as of the Nov 20 close · updated each morning
Turning down, nearing oversold

The stock is 7% below its 20 day and 16% below its 50 day average. It is 6% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the swing low (Nov 17) at $32.46, and the nearest resistance the Pivot at $32.84.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 4.2%/day
Key levels
$43.4952 week high+33.4%
$37.90100 day average+16.3%
$37.7750 day average+15.9%
$34.9720 day average+7.3%
$34.49Swing high (Nov 13)+5.8%
$34.47200 day average+5.8%
$33.17Pivot R1+1.8%
$32.84Pivot+0.8%
$32.59Last close
$32.46Swing low (Nov 17)−0.4%
$32.26Pivot S1−1.0%
$25.9052 week low−20.5%
Indicators
RSI (14)32.47Weak, oversold below 30Neutral
MACD-1.44Below its signal lineBearish
Stochastic9.2Near the bottom of its rangeOversold
ADX (14)35.4Trending down
Williams %R-95.1Oversold below −80, overbought above −20Oversold
CCI (20)-69.3Oversold below −100, overbought above 100Neutral
Rate of change−1.6%Change over 10 sessionsBearish
ATR (14)$1.38Typical daily range, 4.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HRMY

What happened before

See how HRMY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow HRMY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How HRMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for HRMYHow many large options trades hit HRMY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

HRMY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲235 buying vs 110 selling
  • ▲Held by funds +9.8 pts
  • ▲Funds holding +31
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding358327+9.5%
In funds' top 1032+50.0%
Held by funds102.0%92.3%+9.8 pts
New / increased63 / 17250 / 131+29.8%
Reduced / sold out76 / 34107 / 33−21.4%
Put/call ratio5.15––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HRMY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

HRMY Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$6.0M7 sales · 3 insiders
48% of the selling was under pre-arranged trading plans.
2025-12 sold $1.8M2026-01 sold $892K2026-09 sold $3.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 18Kumar BudurChief Medical OfficerSale38,452$43.05$1.7M
Sep 8Kumar BudurChief Medical OfficerSale33,954$42.80$1.5M
Jan 26Sandip KapadiaCFOSale plan3,746$37.15$139K
Jan 15Sandip KapadiaCFOSale plan20,961$35.92$753K
Dec 12, 2025Jeffrey M. DaynoPresident, CEOSale plan25,933$40.11$1.0M
Dec 5, 2025Sandip KapadiaCFOSale plan20,000$39.54$791K
Every insider buy and sale for HRMY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See HRMY insider trades →

From SEC Form 4 filings by HRMY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HRMY is in one of them and how their past HRMY trades turned out.

HRMY in the AI portfolios
Loading…

HRMY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HRMY in an article yet. Here's the latest on the wider market.

HRMY in the news

About Harmony Biosciences Holdings

Harmony Biosciences is a neuroscience company based in Plymouth Meeting, Pennsylvania, that focuses on rare neurological diseases. Its main product, WAKIX, is a prescription tablet taken once a day to treat excessive daytime sleepiness and cataplexy in people with narcolepsy. The company is also developing treatments for other rare conditions, including certain epilepsy syndromes. Healthcare providers prescribe its medicines to patients.

Headquarters
Plymouth Meeting, PA